anti-Sialyl-Tn/CD3 bispecific mAbs (Siamab)

N/A

Report date: 2026/03/19 16:53:43

Base Information

Drug Nameanti-Sialyl-Tn/CD3 bispecific mAbs (Siamab)

Drug Alias Nameanti-CD3/anti-Sialyl-Tn bispecific T-cell engager (Siamab Therapeutics)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionT cell surface glycoprotein CD3 modulators

TargetsT cell surface glycoprotein CD3

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesSiamab Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesSiamab Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A